Table I.
Location of miRNAs down-regulated in MDS (columns 2 and 3), correlation with loci reported to demonstrate losses by aCGH (column 4) [3,4], association with promoter methylation status demonstrated in this study by pyrosequencing (column 5) and correlation with expression of host genes determined by transcriptional profi ling using RMA analysis of MILE study data (column 6) [14,21].
| miRNA | Location | Host gene | aCGH | Promoter methylation status |
Transcriptional profiling |
|---|---|---|---|---|---|
| hsa-mir-103-1 | 5q34 | PANK3 (intron 5) | No sig. difference | No sig. difference | |
| hsa-mir-140 | 16q22.1 | WWP2 (intron 15–16) | Hypermethylated | Down (p < 0.05) | |
| hsa-mir-150 | 19q13.33 | (RPS11) | Loss | No sig. difference | No sig. difference |
| hsa-mir-342 | 14q32.2 | EVL (intron 3) | Loss | No sig. difference | Down (p < 0.05) |
| hsa-mir-378 | 5q32 | PPARGC1B (intron 1) | Loss | Hypermethylated | No sig. difference |
| hsa-mir-483 | 11p15.5 | IGF2 (intron 2–4) | No sig. difference | No sig. difference | |
| hsa-mir-632 | 17q11.2 | ZNF207 (exon 1) | Hypermethylated * | Down (p < 0.05) | |
| hsa-mir-636 | 17q25.1 | SRSF2 (intron 1, exon 2–3) | No sig. difference | No sig. difference |
*
Representative data are shown, see Figure 2.
MDS, myelodysplastic syndromes; aCGH, array comparative genomic hybridization; RMA, robust multichip analysis; MILE, Microarrays in Leukemia; sig., significant.